Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07264959 · ClinicalTrials.gov registry record
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
A clinical trial, sponsored by Blueprint Medicines Corporation.
- Recruiting
- Registry status
- 150
- Enrollment target
NCT07264959: Recruiting study, sponsored by Blueprint Medicines Corporation.
NCT07264959 is a clinical trial that is actively recruiting participants, run by Blueprint Medicines Corporation. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07264959 is actively recruiting participants, sponsored by Blueprint Medicines Corporation.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
Study Summary
This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis and bone manifestations in ISM. Quality of life and disease control will be assessed through participant questionnaires. The study will also evaluate real world ISM treatment management, including use of avapritinib.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2032-12-01 |
What NCT07264959 shows while recruiting
NCT07264959 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07264959 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07264959 about?
NCT07264959 is a clinical study titled "An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)". This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis...
What is the current status of trial NCT07264959?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2026-04-15. Estimated completion is 2032-12-01.
Who is sponsoring clinical trial NCT07264959?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI